10-Q quarterly report · filed Nov 5, 2026

Nkarta, Inc. (NKTX) Q3 2026 10-Q Quarterly Report

Short answer

Nkarta, Inc. (NKTX) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$33M
−53.5% YoY · +17.4% QoQ
EPS (diluted)
−$0.44
−46.7% YoY · +20.0% QoQ

Source: XBRL data from the Nkarta, Inc. (NKTX) Q3 2026 10-Q on SEC EDGAR. USD.

Nkarta, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, with no product sales since inception
  • Operating margin not applicable, net loss $(33.3) million vs $(21.7) million YoY
  • NKX019 R&D spending $11.4 million, up from $4.3 million YoY
  • Cash, restricted cash and investments $216.0 million as of September 30, 2026
  • Operating cash outflow $78.3 million, up from $67.1 million YoY; funding sufficient for at least 12 months

Risk Factors

  • Losses $101.5 million, accumulated deficit $749.8 million as of September 30, 2026
  • Cash, restricted cash and investments $216.0 million, additional financing needed for pivotal trials
  • FDA-agreed amendments enabled outpatient dosing and re-dosing, increasing safety-monitoring and cumulative-toxicity exposure
  • Ntrust-1 and Ntrust-2 enrollment challenges from competition for autoimmune trial sites, investigators and patients
  • Miltenyi CliniMACS Plus system and reagents remain sole-source manufacturing inputs, with four-to-six-month reagent expiration windows

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Nkarta, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.